Eli Lilly (LLY) Capital Expenditures (2009 - 2026)

Eli Lilly (LLY) has reported Capital Expenditures for 18 consecutive years, with $2.3 billion the latest figure, recorded in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $2.3 billion, up 54.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.7 billion (up 55.1% YoY), and the FY2025 annual result was $7.8 billion, up 55.02% from the prior year.
• Capital Expenditures was $2.3 billion for Q1 2026 at Eli Lilly, down from $2.5 billion in the prior quarter.
• Over five years, Capital Expenditures peaked at $2.5 billion in Q4 2025 and troughed at $365.4 million in Q1 2022.
• Average Capital Expenditures over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2023.
• Year-over-year, Capital Expenditures declined 2.7% in 2022 and surged 113.9% in 2023.
• Over 5 years, Capital Expenditures stood at $500.7 million in 2022, then soared by 113.9% to $1.1 billion in 2023, then surged by 39.7% to $1.5 billion in 2024, then jumped by 70.21% to $2.5 billion in 2025, then declined by 8.67% to $2.3 billion in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $2.3 billion in Q1 2026, $2.5 billion in Q4 2025, and $2.1 billion in Q3 2025.